A Phase 1 interventional study of Vortioxetine in Healthy Adult Participants, sponsored by Takeda. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-27.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the bioequivalence of a single oral administration of a vortioxetine (Lu AA21004) 20 mg tablet in comparison with two of vortioxetine 10 mg tablets in Japanese healthy adult participants.
The drug being tested in this study is called vortioxetine (Lu AA21004). Vortioxetine is being tested in Japanese healthy adult participants. This study will look at the bioequivalence of a single oral administration of a vortioxetine 20 mg tablet in comparison with two of vortioxetine 10 mg tablets, and also look at the safety of a single oral dose of vortioxetine 20 mg in Japanese healthy adult participants.
The study will enroll 28 (14 for each sequence) healthy participants. In case bioequivalence cannot be demonstrated with the number of participants initially planned, an add-on participant study may be conducted (as a maximum 28 participants additionally). Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups.
This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 25 days. Participants will make two visits to the clinic and be hospitalized for ten days in total.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
Drug: Vortioxetine
Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
Drug: Vortioxetine
Vortioxetine tablet
Also known as: Lu AA21004
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
Time frame: Up to Day 25
Number of Participants With TEAE Related to Vital Sign
Time frame: Up to Day 25
Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)
Time frame: Up to Day 25
Number of Participants With TEAE Related to 12-lead Electrocardiograms
Time frame: Up to Day 25
Participants took part in the study at 1 investigative site in Japan, from 16 February 2018 to 13 April 2018.
| Milestone | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Tablet |
|---|---|---|
| Started | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
| hour*nanogram per milliliter (h*ng/mL) | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004 | 299.3 ± 59.820 | 301.1 ± 62.070 |
| ng/mL | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004 | 8.744 ± 1.7838 | 8.976 ± 1.6936 |
| h*ng/mL | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004 | 463.9 ± 135.58 | 477.6 ± 164.83 |
| Hours | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004 | 6.000 (6.00 to 8.00) | 6.000 (6.00 to 8.00) |
| Hours | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004 | 67.27 ± 14.145 | 68.84 ± 18.646 |
| Hours | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004 | 30.12 ± 1.8274 | 30.12 ± 1.8335 |
| 1/Hours | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004 | 0.01608 ± 0.0040090 | 0.01599 ± 0.0041766 |
| Hours | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004 | 45.36 ± 9.7694 | 46.44 ± 13.090 |
| Participants | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) | 1 | 0 |
| Participants | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| Number of Participants With TEAE Related to Vital Sign | 0 | 0 |
| Participants | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased) | 1 | 0 |
| Participants | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| Number of Participants With TEAE Related to 12-lead Electrocardiograms | 0 | 0 |
Collected over Up to Day 25. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine One 20 mg Tablet | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| Vortioxetine Two 10 mg Tablets | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Event | Vortioxetine One 20 mg Tablet | Vortioxetine Two 10 mg Tablets |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/28 | 0/28 |
Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.
| Age, Continuous(Years) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Mean | 24.0 ± 6.52 | 24.0 ± 4.96 | 24.0 ± 5.68 |
| Sex: Female, Male(Participants) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 14 | 14 | 28 |
| Race and Ethnicity Not Collected(Participants) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Japan | 14 | 14 | 28 |
| Height(Centimeters (cm)) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Mean | 172.4 ± 3.94 | 170.2 ± 6.48 | 171.3 ± 5.38 |
| Weight(Kilograms (kg)) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Mean | 63.86 ± 6.694 | 61.91 ± 6.254 | 62.89 ± 6.434 |
| BMI(kg/meter (m)^2) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Mean | 21.46 ± 1.812 | 21.33 ± 1.175 | 21.39 ± 1.500 |
| Smoking Classification(Participants) | Vortioxetine One 20 mg Tablet + Two 10 mg Tablets | Vortioxetine Two 10 mg Tablets + One 20 mg Table | Total |
|---|---|---|---|
| Never Smoked | 12 | 13 | 25 |
| Ex-Smoker | 2 | 1 | 3 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Feb 2018 to primary completion in Apr 2018, 1 month.
Results were first posted in Jun 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine